Effect of Anthocyanins on Metabolic Profiles in Subjects With Pre-diabetes
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02689765 |
Recruitment Status :
Completed
First Posted : February 24, 2016
Last Update Posted : December 6, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Insulin Resistance Glucose Metabolism Disorders Type 2 Diabetes Lipid Metabolism Disorders | Dietary Supplement: Anthocyanins Dietary Supplement: Placebo | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 160 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Effect of Anthocyanins on Metabolic Profiles in Subjects With Pre-diabetes: A Randomized, Double-blind, Placebo-controlled Study |
Study Start Date : | February 2016 |
Actual Primary Completion Date : | October 2016 |
Actual Study Completion Date : | October 2016 |

Arm | Intervention/treatment |
---|---|
Experimental: Anthocyanins
Volunteers will be randomised double blinded into 'Anthocyanins' groups(n=60 per group)and given twice daily two capsules of either 80 grams of Anthocyanins, which corresponds a mixture of fresh blue berries and blackcurrants.The total duration of this trial was 24wk.
|
Dietary Supplement: Anthocyanins
Anthocyanins capsules, which comprises different natural Anthocyanins purified from bilberries and blackcurrants
Other Name: Medox |
Placebo Comparator: Control
A daily intake of 320mg Placebo to instead of treatment of Anthocyanins.
|
Dietary Supplement: Placebo
Placebo capsules is identically packaged. |
- Change in fasting glucose and HbA1C [ Time Frame: 12 weeks ]
- The area under the curves for Glucose,insulin and C peptide releasing test(fasting and post 75g oral glucose tolerance test) [ Time Frame: 12 weeks ]
- Lipids [ Time Frame: 12 weeks ]Total cholesterol,Triglycerides,HDL cholesterol,LDL cholesterol,Apolipoprotein A-I ,Apolipoprotein B
- Calculated pancreatic β-cell function and insulin resistance [ Time Frame: 12 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 40 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- FPG 100 mg/dL (5.6 mmol/L) to 125 mg/dL (6.9 mmol/L) (IFG) OR 2-h plasma glucose in the 75gOGTT 140 mg/dL (7.8 mmol/L) to 199 mg/dL (11.0 mmol/L)(IGT) OR HbA1C 5.7-6.4%.
- Newly diagnosed T2DM who exceed the upper limit of the range but has not yet accepted hypoglycemic therapy.
Exclusion Criteria:
Patients with cardiac, renal, or hepatic diseases or with hyperthyroidism or who had concomitant infections, or who use of anti-diabetic drug or potential affect plasma glucose drugs, pregnant and breast-feeding women, and with polycystic ovarian syndrome.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02689765
China, Guangdong | |
Baiyun Street Hospital,Yuexiu District | |
Guangzhou, Guangdong, China, 510100 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | LiPing Yang, PhD, Sun Yat-sen University |
ClinicalTrials.gov Identifier: | NCT02689765 |
Other Study ID Numbers: |
20151218 |
First Posted: | February 24, 2016 Key Record Dates |
Last Update Posted: | December 6, 2016 |
Last Verified: | December 2016 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Diabetes Mellitus Insulin Resistance Prediabetic State Metabolic Diseases Glucose Metabolism Disorders |
Lipid Metabolism Disorders Disease Pathologic Processes Endocrine System Diseases Hyperinsulinism |